Olorofim Aspergillus Infection Study

Summary

The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).

Timeline

Start

2022-04-29

Primary completion

2025-11-18

Completion

2026-03-19

Publications

• Xu H, Liang T, Wang Z, Wei Y, Wan Z, Li R, Zhang L, Liu W. Amino acid substitutions at the G118 hotspot in dihydroorotate dehydrogenase confer olorofim resistance in Aspergillus flavus. Microbiol Spectr. 2026 Aug 4;14(8):e0025126. doi: 10.1128/spectrum.00251-26. Epub 2026 Jul 14.

Drugs

Indications